Drugs that contain Siponimod Fumaric Acid
1. Drug name - MAYZENT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7939519 | NOVARTIS | Immunosuppresant compounds and compositions |
May, 2024
(1 year, 7 months from now) | |
| CN1787817B | NOVARTIS | Immunosuppressant Compounds And Compositions |
Jul, 2015
(7 years ago) | |
| CN1787817A | NOVARTIS | Immunosuppressant Compounds And Compositions |
Jul, 2015
(7 years ago) | |
| CN102174042B | NOVARTIS | Immunosuppressant Compounds And Compositions |
Jul, 2015
(7 years ago) | |
| CN102174042A | NOVARTIS | Immunosuppressant Compound And Composition |
Jul, 2015
(7 years ago) | |
| CN1791592A | NOVARTIS | Immunosuppressant Compounds And Compositions |
Jul, 2015
(7 years ago) | |
| CN1791592B | NOVARTIS | Immunosuppressant Compounds And Compositions |
Jul, 2015
(7 years ago) | |
| CN1816544B | NOVARTIS | Immunosuppressant Compounds And Compositions |
Jul, 2015
(7 years ago) | |
| CN1816544A | NOVARTIS | Immunosuppressant Compounds And Compositions |
Jul, 2015
(7 years ago) | |
| CN1791395A | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| CN1791395B | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| IN234287B | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| IN200503060P4 | NOVARTIS | Immunosuppresant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP1628967A4 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP1633336A4 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP1633336A2 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP1644367A1 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP1644367A4 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP1638551A4 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP1633336B1 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP1638551B1 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP1628967B1 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP1628967A1 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP1644367B1 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP1638551A2 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP2514743A1 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| EP2514743B1 | NOVARTIS | Immunosuppressant Compounds And Compositions |
May, 2024
(1 year, 7 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8492441 | NOVARTIS | Dosage regimen of an S1P receptor agonist |
Nov, 2030
(8 years from now) | |
Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.25MG BASE | TABLET;ORAL | Prescription |
| EQ 1MG BASE | TABLET;ORAL | Prescription |
| EQ 2MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.